Clinical Trials
238 trialsPanitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
Academic and Community Cancer Research United
Cangpo Liujun Prescription on Cancer-related Fatigue in Advanced Colorectal Cancer With Spleen Deficiency and Dampness Excess
First People's Hospital of Hangzhou
PD-1 Antibody Plus Bevacizumab and CAPOX as First-line Treatment for RAS-mut MSS mCRC
Chinese PLA General Hospital
A Study of SC-0191 in Subjects With Metastatic Colorectal Cancer
Shanghai Zhongshan Hospital
Combination of LTC004 and Regorafenib to Treat Patients With Advanced/Metastatic CRC
Tianjin Medical University Cancer Institute and Hospital
SGM-T1
Leiden University Medical Center
Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations
Academic and Community Cancer Research United
VUBAR
Universitair Ziekenhuis Brussel
REGOTORICOX
Sun Yat-sen University
CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy
University of Campania Luigi Vanvitelli
Adebrelimab Plus Cetuximab and Chemotherapy for Patients With RAS/BRAF Wild-Type Unresectable Liver Metastases Colorectal Cancer
The First Affiliated Hospital of Zhengzhou University
Fruquintinib Combined With Tislelizumab and HAIC in Patients With Advanced Colorectal Liver Metastases Cancer Who Failed Standard Therapy
Fudan University
DETECT
Sun Yat-sen University
Bemalenograstim Alfa for the Prevention in Patients With Colorectal Cancer/Pancreatic Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
Cadonilimab Plus FOLFOXIRI and Bevacizumab as First Line Therapy for Metastatic MSS Colorectal Cancer
Fujian Cancer Hospital
AIO-KRK-0116
Ludwig-Maximilians - University of Munich
REVOLUTION
National Cancer Institute, Naples
COSTIC
Sun Yat-sen University
IMPROVE
Fudan University
RC48-ADC Combined With Bevacizumab in HER2-positive Advanced Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University
A Study of JMT101 in Patients With Metastatic Colorectal Cancer
Shanghai JMT-Bio Inc.
PCOX
Sun Yat-sen University
Envafolimab Combined With Trifluridine/Tipiracil and Bevacizumab in the Treatment of Refractory mCRC.
The First Affiliated Hospital with Nanjing Medical University
High Dose Vitamin C Combined With Metformin in the Treatment of Malignant Tumors
Zhongnan Hospital
Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
IFOM ETS - The AIRC Institute of Molecular Oncology
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
Holy Stone Healthcare Co., Ltd
The Efficacy and Safety of Fruquintinib Plus Chemotherapy as Second-line Treatment in Metastatic Colorectal Cancer
Fudan University
Fruquintinib With mFOLFOX6/FOLFIRI as First-Line Therapy for Conversion Surgery in mCRC
Fudan University
INTERACT-II
Catharina Ziekenhuis Eindhoven
SIRTCI
Federation Francophone de Cancerologie Digestive
Phase 2a Study to Evaluate Suppression of 5-Fluorouracil -Induced Mucositis by TK112690
Tosk, Inc.
The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation
Shanghai Henlius Biotech
Sintilimab and Chidamide in Combination With or Without IBI305 in Advanced or Metastatic pMMR/MSS Colorectal Carcinoma
Sun Yat-sen University
Fruquintinib Plus FOLFIRI in RAS-mutated Metastatic Colorectal Cancer
Hunan Cancer Hospital
Effect of Losartan on the Incidence and Severity of Chemotherapy-Induced Mucositis in Gastrointestinal Cancer Patients
Ain Shams University
Surufatinib, Toripalimab and Chemotherapy in Second-line MT and MSS CRC
Zhejiang University
MSI-H/dMMR
Henan Cancer Hospital
Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
University of Kansas Medical Center
Serplulimab+Regorafenib +Hepatic Artery Bicarbonate Infusion in Patients With Colorectal Cancer and Liver Metastases
Second Affiliated Hospital, School of Medicine, Zhejiang University
Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)
University of Kansas Medical Center
mCRC
Shanghai Kechow Pharma, Inc.
HEM1036 Phase 2 Study in Low Anterior Resection Syndrome
HEM Pharma Inc.
QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC
Qilu Pharmaceutical Co., Ltd.
VIVA
Ospedale Policlinico San Martino
Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
Fujian Cancer Hospital
FOLFOX/FOLFIRI Containing Levofolinic Acid (Zuoyu ®) in the Treatment of Unresectable or Metastatic Colorectal Cancer
China Medical University, China
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
Shanghai Zhongshan Hospital
HIPEC
National Cancer Institute, Naples
PACER
National Cancer Institute, Naples
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer
Second Affiliated Hospital, School of Medicine, Zhejiang University